Search

Your search keyword '"Gatell, J."' showing total 916 results

Search Constraints

Start Over You searched for: Author "Gatell, J." Remove constraint Author: "Gatell, J."
916 results on '"Gatell, J."'

Search Results

1. Trends in mortality in people with HIV from 1999 to 2020: a multi-cohort collaboration

2. Innovative Bit Body Design Unveils Manufacturing Novelty, Improves Drilling Performance and Dogleg Assurance in Rotary Steerable Applications

6. Risk for non-AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy

8. Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response:a sub-study of the NEAT001/ANRS143 randomized trial

9. Risk for non-AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy: A multinational prospective cohort study

10. Incidence of cancer and overall risk of mortality in individuals treated with raltegravir‐based and non‐raltegravir‐based combination antiretroviral therapy regimens

11. Promoting high standards of care for women living with HIV: position statement from the Women Against Viruses in Europe Working Group

12. The extent of B‐cell activation and dysfunction preceding lymphoma development in HIV‐positive people†

13. Week 96 results of the randomized, multicentre Maraviroc Switch (MARCH) study

14. HIV in the Intensive Care Unit

15. Tenofovir disoproxil fumarate/emtricitabine plus ritonavir-boosted lopinavir or cobicistat-boosted elvitegravir as a single-tablet regimen for HIV post-exposure prophylaxis

21. Clinical progression of severely immunosuppressed HIV-infected patients depends on virological and immunological improvement irrespective of baseline status

22. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

23. Long‐term effectiveness of recommended boosted protease inhibitor‐based antiretroviral therapy in Europe

24. Gender differences in the use of cardiovascular interventions in HIV‐positive persons; the D:A:D Study

25. Epidemiological changes of acute/recent human immunodeficiency virus type 1 infection in Barcelona, Spain (1997–2015): a prospective cohort study

29. Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV

30. Estimating prevalence of accumulated HIV-1 drug resistance in a cohort of patients on antiretroviral therapy

33. Sensitive testing of plasma HIV-1 RNA and Sanger sequencing of cellular HIV-1 DNA for the detection of drug resistance prior to starting first-line antiretroviral therapy with etravirine or efavirenz

36. Highlights of the 2017 European AIDS Clinical Society (EACS) Guidelines for the treatment of adult HIV-positive persons version 9.0

37. The EuroSIDA study: 25 years of scientific achievements

38. Week 48 Resistance Analyses of the Once-Daily, Single-Tablet Regimen Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Adults Living with HIV-1 from the Phase III Randomized AMBER and EMERALD Trials

43. The EuroSIDA study:25 years of scientific achievements

49. Comparison of two HIV testing strategies in primary care centres: indicator-condition-guided testing vs. testing of those with non-indicator conditions

Catalog

Books, media, physical & digital resources